Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-10449238-B2
Application number	US-201916385221-A
Country	US
Kind code	B2
Filing date	Apr 16, 2019
Priority date	Aug 5, 2015
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1),
wherein said cancer is selected from small cell lung cancer, melanoma, benign prostate hyperplasia, and prostate cancer.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

7. The method of claim 6 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

10. The method of claim 9 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

11. The method of claim 10 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

12. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

13. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

14. The method of claim 9 , wherein the contacting is in vitro.

15. The method of claim 1 , wherein the cancer cells present the peptide at a level at least 1.2-fold of that present in normal tissue.

16. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1).

17. A method of eliciting an immune response in a patient who has small cell lung cancer, melanoma, benign prostate hyperplasia, or prostate cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1), thereby inducing a T-cell response to the small cell lung cancer, melanoma, benign prostate hyperplasia, or prostate cancer.

18. The method of claim 17 , wherein the T cell response comprises a cytotoxic T cell response.

19. The method of claim 17 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1).

20. The method of claim 1 , wherein the cancer is prostate cancer.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• G01N2570/00

  Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title